Published in Eur J Immunol on April 10, 2013
Role of macrophage migration inhibitory factor (MIF) in pollen-induced allergic conjunctivitis and pollen dermatitis in mice. PLoS One (2015) 1.39
A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke. Metab Brain Dis (2014) 0.95
Preclinical evaluation of recombinant T cell receptor ligand RTL1000 as a therapeutic agent in ischemic stroke. Transl Stroke Res (2014) 0.92
HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis. J Immunol (2014) 0.91
Novel humanized recombinant T cell receptor ligands protect the female brain after experimental stroke. Transl Stroke Res (2014) 0.90
Predicted structure of MIF/CD74 and RTL1000/CD74 complexes. Metab Brain Dis (2016) 0.82
Sex differences in the immune response to experimental stroke: Implications for translational research. J Neurosci Res (2017) 0.78
Sex-dependent treatment of chronic EAE with partial MHC class II constructs. J Neuroinflammation (2017) 0.76
Partial MHC class II constructs as novel immunomodulatory therapy for stroke. Neurochem Int (2016) 0.76
HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection. J Neuroinflammation (2015) 0.76
CD74 in Kidney Disease. Front Immunol (2015) 0.75
The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis. Metab Brain Dis (2014) 0.75
Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke. Neurochem Int (2016) 0.75
Invariant Chain Complexes and Clusters as Platforms for MIF Signaling. Cells (2017) 0.75
CD74/DQA1 dimers predispose to the development of arthritis in humanized mice. Immunology (2015) 0.75
Macrophage migration inhibitory factor (MIF) modulates trophic signaling through interaction with serine protease HTRA1. Cell Mol Life Sci (2017) 0.75
MIF and D-DT are potential disease severity modifiers in male MS subjects. Proc Natl Acad Sci U S A (2017) 0.75
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Caspases: enemies within. Science (1998) 19.45
Death receptors: signaling and modulation. Science (1998) 16.95
Immunology of multiple sclerosis. Annu Rev Immunol (2005) 9.08
Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol (2003) 5.85
MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature (1993) 5.60
The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med (1994) 5.55
MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med (2007) 5.28
MIF as a glucocorticoid-induced modulator of cytokine production. Nature (1995) 5.21
MIF signal transduction initiated by binding to CD74. J Exp Med (2003) 4.79
The many roles of FAS receptor signaling in the immune system. Immunity (2009) 4.67
Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci (2011) 4.21
A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med (1999) 4.15
Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry (1994) 3.58
CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity (2006) 3.38
Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A (2001) 3.29
Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med (1999) 3.23
Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med (2007) 3.09
Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J Exp Med (1990) 2.42
Invariant chain structure and MHC class II function. Cell (1996) 1.79
The effects of macrophage depletion on the clinical and pathologic expression of experimental allergic encephalomyelitis. J Immunol (1981) 1.79
Human major histocompatibility complex class II invariant chain is expressed on the cell surface. J Biol Chem (1990) 1.77
The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell (1993) 1.58
The role of macrophages, perivascular cells, and microglial cells in the pathogenesis of experimental autoimmune encephalomyelitis. Glia (1995) 1.55
A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett (2009) 1.54
Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE. J Neurochem (2006) 1.26
Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitis. J Neuroimmunol (2008) 1.26
Major differences in the responses of primary human leukocyte subsets to IFN-beta. J Immunol (2010) 1.26
Macrophage migration inhibitory factor and CD74 regulate macrophage chemotactic responses via MAPK and Rho GTPase. J Immunol (2011) 1.19
Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J Neuroimmunol (2011) 1.13
Male SJL mice do not relapse after induction of EAE with PLP 139-151. J Neurosci Res (1996) 1.11
A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance. J Autoimmun (2012) 1.10
Macrophage migration inhibitory factor increases leukocyte-endothelial interactions in human endothelial cells via promotion of expression of adhesion molecules. J Immunol (2010) 1.09
Cutting edge: macrophage migration inhibitory factor is necessary for progression of experimental autoimmune encephalomyelitis. J Immunol (2005) 1.08
RTL therapy for multiple sclerosis: a Phase I clinical study. J Neuroimmunol (2010) 1.04
Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice. Clin Immunol (2007) 1.02
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study. Autoimmune Dis (2012) 0.93
Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult Scler (2004) 0.81
Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med (2005) 8.49
MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med (2007) 5.28
MIF signal transduction initiated by binding to CD74. J Exp Med (2003) 4.79
Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab (2006) 3.91
CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity (2006) 3.38
Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol (2004) 3.34
Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A (2001) 3.29
Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol (2006) 3.28
Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature (2008) 2.96
T- and B-cell-deficient mice with experimental stroke have reduced lesion size and inflammation. J Cereb Blood Flow Metab (2007) 2.75
Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res (2005) 2.39
Fibrocytes: emerging effector cells in chronic inflammation. Nat Rev Immunol (2011) 2.26
Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol (2006) 2.09
Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology (2005) 2.05
"Undiagnosing" multiple sclerosis: the challenge of misdiagnosis in MS. Neurology (2012) 1.94
A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice. J Immunol (2010) 1.91
Fibrocytes in health and disease. Exp Hematol (2010) 1.90
Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. Proc Natl Acad Sci U S A (2011) 1.85
High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res (2002) 1.84
GPR30 contributes to estrogen-induced thymic atrophy. Mol Endocrinol (2007) 1.78
The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep (2006) 1.78
Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol (2004) 1.77
Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Proc Natl Acad Sci U S A (2007) 1.76
The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol (2007) 1.73
Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem (2007) 1.71
Regulatory B cells limit CNS inflammation and neurologic deficits in murine experimental stroke. J Neurosci (2011) 1.63
A critical role for the host mediator macrophage migration inhibitory factor in the pathogenesis of malarial anemia. J Exp Med (2006) 1.61
Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). Int Immunol (2007) 1.59
Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter. FEBS Lett (2003) 1.59
Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J Clin Invest (2007) 1.57
Advanced glycation endproducts in nondiabetic patients with obstructive sleep apnea. Sleep (2006) 1.57
Impaired macrophage migration inhibitory factor-AMP-activated protein kinase activation and ischemic recovery in the senescent heart. Circulation (2010) 1.56
Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc Natl Acad Sci U S A (2002) 1.55
Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view. Mediators Inflamm (2013) 1.54
Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology (2014) 1.54
Macrophage migration inhibitory factor is released from pituitary folliculo-stellate-like cells by endotoxin and dexamethasone and attenuates the steroid-induced inhibition of interleukin 6 release. Endocrinology (2004) 1.54
A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett (2009) 1.54
Macrophage migration inhibitory factor mediates the antidepressant actions of voluntary exercise. Proc Natl Acad Sci U S A (2012) 1.53
The anemia of malaria infection: role of inflammatory cytokines. Curr Hematol Rep (2004) 1.53
Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal (2005) 1.53
Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. J Neurosci Res (2003) 1.53
The protective effect of 17beta-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-alpha. Am J Pathol (2003) 1.49
A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res (2008) 1.49
MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ Res (2009) 1.49
Macrophage migration inhibitory factor (MIF): a promising biomarker. Drug News Perspect (2010) 1.48
Pure Hemozoin is inflammatory in vivo and activates the NALP3 inflammasome via release of uric acid. J Immunol (2009) 1.48
Endotoxin-induced myocardial dysfunction: effects of macrophage migration inhibitory factor neutralization. Circ Res (2005) 1.48
Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. J Clin Invest (2009) 1.48
IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci U S A (2007) 1.47
Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1. J Immunol (2009) 1.46
Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J Neurosci Res (2006) 1.46
A tautomerase-null macrophage migration-inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation. Mol Cell Biol (2009) 1.43
Imbalance in multiple sclerosis: a result of slowed spinal somatosensory conduction. Somatosens Mot Res (2008) 1.42
Age-associated elevation in TLR5 leads to increased inflammatory responses in the elderly. Aging Cell (2011) 1.39
Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem (2009) 1.39
Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. Curr Neurol Neurosci Rep (2009) 1.37
Recombinant TCR ligand induces early TCR signaling and a unique pattern of downstream activation. J Immunol (2003) 1.37
Macrophage migration inhibitory factor. Crit Care Med (2002) 1.36
Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum (2006) 1.35
Recombinant T cell receptor ligand treats experimental stroke. Stroke (2009) 1.33
Centella asiatica accelerates nerve regeneration upon oral administration and contains multiple active fractions increasing neurite elongation in-vitro. J Pharm Pharmacol (2005) 1.33
Identification of Bphs, an autoimmune disease locus, as histamine receptor H1. Science (2002) 1.33